CONVERGE Post-Approval Study (PAS)
NCT: NCT05393180 · ACTIVE_NOT_RECRUITING
Brief Summary
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Frequently Asked Questions
What is CONVERGE Post-Approval Study (PAS)?
CONVERGE Post-Approval Study (PAS) is a clinical trial registered under NCT05393180. Current status: ACTIVE_NOT_RECRUITING.
What is the status of NCT05393180?
The current status of NCT05393180 (CONVERGE Post-Approval Study (PAS)) is: ACTIVE_NOT_RECRUITING.
When did CONVERGE Post-Approval Study (PAS) start?
CONVERGE Post-Approval Study (PAS) started on 2022-04-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.